What is the appropriate treatment for acute uveitis with posterior synechiae?

Treatment of Acute Uveitis with Posterior Synechiae

For acute anterior uveitis with posterior synechiae, initiate intensive topical corticosteroids (prednisolone acetate 1%) combined with cycloplegic agents to break existing synechiae and prevent further formation, with urgent ophthalmology referral within 2 days. 1

Immediate Management Algorithm

First-Line Therapy

• Topical corticosteroids: Prednisolone acetate 1% is the preferred agent 2, 3, 4

  • Initial dosing: 6 times daily while awake is most commonly used, though practice varies 4
  • Alternative: Difluprednate may be considered if inadequate response within 2-3 weeks 4

• Cycloplegic agents: Essential component to break posterior synechiae and prevent pupillary seclusion 1, 5

  • Cyclopentolate 1% is specifically recommended 5
  • Prevents progression to pupillary seclusion and associated glaucoma

Monitoring and Follow-up

• Initial follow-up within 1 week for most cases 4
• For grade 2 anterior uveitis (which includes cases with posterior synechiae requiring medical intervention): ophthalmology referral within 2 days prior to initiating treatment 1

When to Escalate Beyond Topical Therapy

Indications for Systemic Immunosuppression

The presence of posterior synechiae represents an ocular complication that may warrant earlier systemic therapy 6. Consider systemic treatment if:

1. Ongoing inflammation despite topical steroids after 3 months 3

2. Poor prognostic factors present, including:

   • Posterior synechiae (as a complication) 6
   • Visual acuity worse than 20/100
   • Macular edema
   • Ocular hypotony 7

3. Inability to taper topical steroids below 1-2 drops daily without recurrence 2

Systemic Treatment Hierarchy

For patients requiring systemic therapy:

1. First-line: Methotrexate 3, 7

   • Subcutaneous route preferred over oral 2
   • Achieves remission in approximately 52% of posterior uveitis cases 8

2. Severe cases with sight-threatening complications (including extensive posterior synechiae):

   • Start methotrexate AND monoclonal antibody TNF inhibitor immediately rather than methotrexate monotherapy 2
   • This prevents permanent vision loss in severe presentations

3. Second-line biologics (if methotrexate fails or is not tolerated):

   • Adalimumab or infliximab (monoclonal antibody TNF inhibitors) preferred over etanercept 2
   • Adalimumab extended time to treatment failure from 13 to 24 weeks and reduced treatment failure from 78.5% to 54.5% 8

4. Third-line options (after failing 2 TNF inhibitors):

   • Abatacept, tocilizumab, mycophenolate, leflunomide, or cyclosporine 2
   • Mycophenolate mofetil controlled inflammation in 70.9% of cases 8

Critical Pitfalls to Avoid

Do not start corticosteroids before ophthalmology examination - this may worsen infectious causes (herpetic keratitis/uveitis) or mask accurate diagnosis 1

Monitor for corticosteroid complications: The risk of elevated intraocular pressure and cataracts increases with ≥2 drops daily and longer duration 2. Prednisolone ≤3 drops daily is preferred to minimize cataract risk.

Recognize when topical therapy alone is insufficient: If requiring ongoing topical steroids at 1-2 drops daily for ≥3 months, systemic therapy should be added to enable steroid discontinuation 2

Special Consideration: Adjunctive Therapy

For extensive recent-onset posterior synechiae with impending pupillary seclusion despite maximum anti-inflammatory therapy, intracameral tissue plasminogen activator (3 μg in 0.05 mL) may provide rapid synechiolysis within 24 hours 9. This is an adjunctive measure used alongside intensive topical corticosteroids and cycloplegics.

Treatment Duration

Continue topical corticosteroids with gradual taper based on response. For systemic therapy, maintain inactive disease for 2 years off topical steroids before reducing systemic immunosuppression 3. The goal is zero anterior chamber cells 3.